MPP Strikes Landmark Licensing Deal With Novartis On Nilotinib
Agreement On Tasigna Generics Represents First Such Deal For A Cancer Medicine
Executive Summary
The Medicines Patent Pool has struck a milestone voluntary licensing deal with new partner Novartis for nilotinib to treat chronic myeloid leukemia, representing the first MPP agreement in non-communicable diseases as well as the “first ever public health-oriented voluntary license agreement on a cancer medicine.”
You may also be interested in...
What’s Next? Five Things To Look Out For In December
In a busy final month of the year, key legal action will be heard in both the US and Europe, while the Medicines Patent Pool will hear from applicants for a milestone voluntary licensing agreement covering Novartis’ nilotinib.
Negotiators Prioritize Generic And Biosimilar Oncology Drugs Over Newer Medicines
The Union for International Cancer Control and the World Health Organization are prioritizing off-patent drugs in their efforts to facilitate oncology medicine access in developing nations.
Deal Watch: OrsoBio Reveals Its Metabolic Health Focus With Four Licensing Pacts
California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.